NCT06386302View on ClinicalTrials.gov

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

NARecruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

August 5, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions
AMLAcute Myeloid Leukemia
Interventions
DRUG

Chidamide

30 mg/d orally twice-weekly

DRUG

Venetoclax

100 mg d1 200 mg d 2 400 mg d3-d28 Orally

DRUG

azacitidine

75 mg/m 2 /d subcutaneous injection or IV d1-d7

Trial Locations (1)

300020

RECRUITING

Blood Hospital, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER